mRCC Roundtable Discussion

Roundtable Discussions Provide Actionable Advice on Market Moving Opportunities!

Each one of the 3 images below is hyperlinked to a video clip of clinician opinion obtained in a roundtable discussion moderated by Dr. Nicolas Vogelzang and focusing on the future treatment of metastatic renal cell cancer (mRCC).

Key Takeaway

Opdivo® (nivolumab) is of
most interest to community oncologists
treating mRCC.

Key Takeaway

Opdivo (nivolumab) is most likely
to be the future agent of choice for the
second-line treatment of mRCC.

Key Takeaway

Opdivo (nivolumab) is most likely
to be offered to patients whose disease has
progressed on first-line therapy.

Actionable Insight
Opdivo (nivolumab) is becoming the new drug of choice for the second line treatment of mRCC.

Precision Medicine
Market Research

Click on the slide below to view a Premier Endpoint
case example slide deck of market research focused
on clinician opinion of precision medicine.

Precision_medicine_PDF_grab

The Pharma Company
Sponsor Challenge

Click on the slide below to view a Premier Endpoint
case example slide deck of market research designed to gauge how an
educational website is impacting the care of patients with cancer.

Pharma_Company_PDF_grab

Online Learning Centers

Online Learning Centers Offer Marketing Solutions to Reach and Engage Target Audiences:

Hepatitis C: Streening, Diagnosis, Treatment, and Management

Premier Endpoint has the capability to develop online learning centers to reach and engage target clinician audiences with the latest information on medical disorders, medical devices, and therapies.

We invite you to contact us with any questions about how our services can help you succeed or to discuss the projects in which we've benefited others: KCzobor@PremierEndpoint.com